Simmons Bank continued to hold its stake in Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,010 shares of the medical research company’s stock at the close of the 2nd quarter. Simmons Bank’s holdings in Edwards Lifesciences Corporation were worth $475,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Dynamic Technology Lab Private Ltd acquired a new position in Edwards Lifesciences Corporation during the 1st quarter valued at $291,000. BB&T Securities LLC raised its stake in Edwards Lifesciences Corporation by 48.7% during the 1st quarter. BB&T Securities LLC now owns 7,174 shares of the medical research company’s stock valued at $674,000 after purchasing an additional 2,349 shares during the last quarter. ZWJ Investment Counsel Inc. acquired a new position in Edwards Lifesciences Corporation during the 1st quarter valued at $1,082,000. Rafferty Asset Management LLC acquired a new position in Edwards Lifesciences Corporation during the 1st quarter valued at $896,000. Finally, Credit Agricole S A raised its stake in Edwards Lifesciences Corporation by 25.6% during the 1st quarter. Credit Agricole S A now owns 171,469 shares of the medical research company’s stock valued at $16,131,000 after purchasing an additional 34,997 shares during the last quarter. Institutional investors and hedge funds own 82.12% of the company’s stock.

Edwards Lifesciences Corporation (EW) traded down 0.668% on Monday, reaching $110.715. 240,296 shares of the company’s stock were exchanged. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The stock’s 50 day moving average is $111.90 and its 200 day moving average is $110.77. The company has a market cap of $23.38 billion, a price-to-earnings ratio of 33.581 and a beta of 0.62.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The company had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.76 earnings per share. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

In related news, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $114.80, for a total value of $3,776,920.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 182,201 shares of company stock worth $20,768,154. Company insiders own 2.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Simmons Bank Has $475,000 Holdings in Edwards Lifesciences Corporation (EW)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/09/simmons-bank-has-475000-holdings-in-edwards-lifesciences-corporation-ew.html.

Several research firms recently commented on EW. Barclays PLC reiterated an “equal weight” rating and set a $120.00 target price on shares of Edwards Lifesciences Corporation in a research note on Saturday, September 30th. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Royal Bank Of Canada reiterated a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. BMO Capital Markets reiterated a “buy” rating and set a $132.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Finally, William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences Corporation in a research note on Monday, August 28th. Seven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $120.75.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.